DOCSLIB.ORG

Annexure‐ I : Specifications of FDA Approved Drug Library

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annexure‐ I : Specifications of FDA Approved Drug Library Annexure‐ I : Specifications of FDA approved drug library All compounds should have been approved by FDA Bioactivity and safety of each compound should have been confirmed by clinical trials Compounds should be related to oncology, cardiology, anti‐inflammatory, immunology, neuropsychiatry, analgesia etc. The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format. Should be compatible for high throughput screening (HTS) and high content screening (HCS) The library should contain following 1443 compounds: Sl. No Name of the compound 1. ABT‐263 (Navitoclax) 2. Linifanib (ABT‐869) 3. Veliparib (ABT‐888) 4. Axitinib 5. Saracatinib (AZD0530) 6. FG‐4592 7. Selumetinib (AZD6244) 8. Nintedanib (BIBF 1120) 9. Afatinib (BIBW2992) 10. Bortezomib (PS‐341) 11. Bosutinib (SKI‐606) 12. Cediranib (AZD2171) 13. Dovitinib (TKI‐258, CHIR‐258) 14. Dasatinib 15. Erlotinib HCl (OSI‐744) 16. Gefitinib (ZD1839) 17. Imatinib Mesylate (STI571) 18. Lapatinib (GW‐572016) Ditosylate 19. Lenalidomide (CC‐5013) 20. Panobinostat (LBH589) 21. Nilotinib (AMN‐107) 22. Pazopanib HCl 23. Rapamycin (Sirolimus) 24. Sorafenib Tosylate 25. Sunitinib Malate 26. Temsirolimus (CCI‐779, NSC 683864) 27. Vandetanib (ZD6474) 28. Vorinostat (SAHA, MK0683) 29. VX‐680 (Tozasertib, MK‐0457) 30. Entinostat (MS‐275) 31. Enzastaurin (LY317615) 32. Olaparib (AZD2281, Ku‐0059436) 33. Masitinib (AB1010) 34. GDC‐0941 35. Crizotinib (PF‐02341066) 36. Vismodegib (GDC‐0449) 37. Belinostat (PXD101) 38. Iniparib (BSI‐201) 39. PCI‐24781 (Abexinostat) 40. OSI‐906 (Linsitinib) 41. Quisinostat (JNJ‐26481585) 42. Rucaparib (AG‐014699,PF‐01367338) 43. Vatalanib (PTK787) 2HCl 44. Foretinib (GSK1363089) 45. Triciribine 46. Cabozantinib (XL184, BMS‐907351) 47. Everolimus (RAD001) 48. Mocetinostat (MGCD0103) 49. YM155 (Sepantronium Bromide) 50. Alisertib (MLN8237) 51. Malotilate 52. 17‐AAG (Tanespimycin) 53. Ivacaftor (VX‐770) 54. Barasertib (AZD1152‐HQPA) 55. Docetaxel 56. Paclitaxel 57. Roscovitine (Seliciclib,CYC202) 58. Capecitabine 59. CEP‐18770 (Delanzomib) 60. Ganetespib (STA‐9090) 61. AT13387 62. Lenvatinib (E7080) 63. Valproic acid sodium salt (Sodium valproate) 64. Regorafenib (BAY 73‐4506) 65. Ritonavir 66. Anastrozole 67. Aprepitant 68. Bicalutamide 69. Fulvestrant 70. Raltitrexed 71. Thalidomide 72. CUDC‐101 73. TAK‐700 (Orteronel) 74. Exemestane 75. Finasteride 76. Irinotecan 77. Cladribine 78. Decitabine 79. Dimesna 80. Dutasteride 81. Melatonin 82. Bisoprolol fumarate 83. Tivozanib (AV‐951) 84. Doxorubicin (Adriamycin) 85. Fluorouracil (5‐Fluoracil, 5‐FU) 86. Methotrexate 87. Imiquimod 88. Bendamustine HCl 89. Nelarabine 90. Bleomycin Sulfate 91. Clofarabine 92. Dacarbazine 93. Dexrazoxane HCl (ICRF‐187, ADR‐529) 94. Epirubicin HCl 95. Oxaliplatin 96. Etoposide 97. Raloxifene HCl 98. Fludarabine Phosphate 99. Flavopiridol (Alvocidib) 100. Topotecan HCl 101. Letrozole 102. Temozolomide 103. Tamoxifen 104. Vincristine 105. Agomelatine 106. Amuvatinib (MP‐470) 107. Leflunomide 108. Enzalutamide (MDV3100) 109. Dienogest 110. Entecavir Hydrate 111. Nepafenac 112. Rufinamide 113. Posaconazole 114. Prasugrel 115. Ramelteon 116. Cinacalcet HCl 117. Celecoxib 118. Avagacestat (BMS‐708163) 119. Vemurafenib (PLX4032, RG7204) 120. Acarbose 121. Adapalene 122. Altretamine 123. Amisulpride 124. Aniracetam 125. Artemisinin 126. Asenapine 127. Benazepril HCl 128. Budesonide 129. Bumetanide 130. Carmofur 131. Cetirizine DiHCl 132. Cilnidipine 133. Cilostazol 134. Floxuridine 135. FT‐207 (NSC 148958) 136. Ifosfamide 137. Megestrol Acetate 138. Mercaptopurine (6‐MP) 139. Streptozotocin (STZ) 140. Dexamethasone (DHAP) 141. Doxazosin Mesylate 142. Edaravone 143. Ellagic acid 144. Etodolac 145. Etomidate 146. Felbamate 147. Fluconazole 148. Flumazenil 149. Fluoxetine HCl 150. Fluvoxamine maleate 151. Gatifloxacin 152. Genistein 153. Glimepiride 154. Ivermectin 155. Ketoconazole 156. Lansoprazole 157. Levetiracetam 158. Lidocaine 159. Loratadine 160. Losartan Potassium (DuP 753) 161. Rigosertib (ON‐01910) 162. Epothilone B (EPO906, Patupilone) 163. Amonafide 164. Acitretin 165. Bafetinib (INNO‐406) 166. Doripenem Hydrate 167. Gestodene 168. Drospirenone 169. Ruxolitinib (INCB018424) 170. Isotretinoin 171. Lopinavir 172. Meropenem 173. Mianserin HCl 174. Mosapride Citrate 175. Nafamostat Mesylate 176. Omeprazole 177. Ondansetron HCl 178. Oxcarbazepine 179. Pelitinib (EKB‐569) 180. Pizotifen Malate 181. Resveratrol 182. Rocuronium Bromide 183. Stavudine (d4T) 184. Tenofovir Disoproxil Fumarate 185. Tenofovir 186. Tigecycline 187. Trilostane 188. Vecuronium Bromide 189. Linezolid 190. Alfuzosin HCl 191. Clopidogrel 192. Prazosin HCl 193. Ranolazine 2HCl 194. Repaglinide 195. Rolipram 196. Sildenafil Citrate 197. Sumatriptan Succinate 198. Tamsulosin 199. Tianeptine sodium 200. Tizanidine HCl 201. Topiramate 202. Tranilast 203. Venlafaxine 204. Voriconazole 205. Zileuton 206. Ziprasidone HCl 207. Zonisamide 208. Ispinesib (SB‐715992) 209. Cilomilast 210. Zibotentan (ZD4054) 211. Atazanavir Sulfate 212. Ofloxacin 213. Marbofloxacin 214. Moxifloxacin HCl 215. Doxercalciferol 216. Alfacalcidol 217. TSU‐68 (SU6668, Orantinib) 218. Safinamide Mesylate 219. Pimasertib (AS‐703026) 220. VX‐222 (VCH‐222, Lomibuvir) 221. Zosuquidar (LY335979) 3HCl 222. Daclatasvir (BMS‐790052) 223. Iloperidone 224. Naratriptan 225. Ponatinib (AP24534) 226. Fludarabine 227. Pralatrexate 228. Betamethasone 229. Mycophenolate Mofetil 230. Dyphylline 231. Aztreonam 232. Irbesartan 233. Alprostadil 234. Norfloxacin 235. Lactulose 236. Tadalafil 237. Cyclosporine 238. Pracinostat (SB939) 239. Natamycin 240. SAR245409 (XL765) 241. Quizartinib (AC220) 242. Telaprevir (VX‐950) 243. Saxagliptin 244. EX 527 (Selisistat) 245. Febuxostat 246. Dapagliflozin 247. Nebivolol 248. Pimobendan 249. VX‐809 (Lumacaftor) 250. Pomalidomide 251. Tazarotene 252. Fasudil (HA‐1077) HCl 253. BIRB 796 (Doramapimod) 254. Sulfasalazine 255. Candesartan 256. Apixaban 257. Semagacestat (LY450139) 258. Reserpine 259. Furosemide 260. Olmesartan Medoxomil 261. Cefdinir 262. Clotrimazole 263. Rizatriptan Benzoate 264. Pyridostigmine Bromide 265. Methimazole 266. Metolazone 267. Cefoperazone 268. Silodosin 269. Riluzole 270. Risperidone 271. Sulfapyridine 272. Sulfameter 273. Prilocaine 274. Darunavir Ethanolate 275. Theophylline 276. Prednisone 277. Acetylcysteine 278. Alendronate 279. Ethinyl Estradiol 280. Naproxen 281. Nitazoxanide 282. Triamcinolone Acetonide 283. Orlistat 284. Allopurinol 285. Zafirlukast 286. Acetaminophen 287. Erythromycin 288. Amphotericin B 289. Ibuprofen 290. Amprenavir 291. Albendazole 292. Chlorothiazide 293. Methyldopa 294. Ursodiol 295. Nitrofural 296. Ketoprofen 297. Ketorolac 298. Adenosine 299. Zolmitriptan 300. Telbivudine 301. Monobenzone 302. Tretinoin 303. Phenylbutazone 304. Ezetimibe 305. Enalaprilat Dihydrate 306. Dofetilide 307. Isradipine 308. Estrone 309. Flucytosine 310. Trichlormethiazide 311. Loteprednol etabonate 312. （6‐）ε‐Aminocaproic acid 313. Aminoglutethimide 314. Aminophylline 315. Amorolfine HCl 316. Chloramphenicol 317. Flurbiprofen 318. Disulfiram 319. Mesalamine 320. Ipratropium Bromide 321. Sulfanilamide 322. Betamethasone Dipropionate 323. Meprednisone 324. Betamethasone valerate (Betnovate) 325. Praziquantel 326. Busulfan 327. Carbamazepine 328. Hydrocortisone 329. Torsemide 330. Desonide 331. Didanosine 332. Divalproex Sodium 333. Emtricitabine 334. Progesterone 335. Lamivudine 336. Eplerenone 337. Hydrochlorothiazide 338. Estradiol 339. Deferasirox 340. Piroxicam 341. Gemcitabine 342. Glipizide 343. Glyburide 344. Fomepizole 345. Adefovir Dipivoxil 346. Zalcitabine 347. Azathioprine 348. Indomethacin 349. Paliperidone 350. Terbinafine 351. Levonorgestrel 352. Gemfibrozil 353. Indapamide 354. Mitotane 355. Methylprednisolone 356. Meloxicam 357. Mesna 358. Methocarbamol 359. Prednisolone 360. Telmisartan 361. Thiabendazole 362. Guaifenesin 363. Rifabutin 364. Nevirapine 365. Esomeprazole Magnesium 366. Nicotinic Acid 367. Nimodipine 368. Nisoldipine 369. Oxybutynin 370. Enoxacin 371. Pitavastatin Calcium 372. Rifapentine 373. Suprofen 374. Pyrazinamide 375. Quetiapine Fumarate 376. Rifampin 377. Cefditoren Pivoxil 378. Sulfadiazine 379. Chlorprothixene 380. Oxytetracycline (Terramycin) 381. Toremifene Citrate 382. Ethionamide 383. Trifluridine 384. Azacitidine 385. Vidarabine 386. Teniposide 387. Stanozolol 388. Tetrabenazine (Xenazine) 389. Rifaximin 390. Simvastatin 391. Ramipril 392. Fenofibrate 393. Ranolazine 394. Ranitidine 395. Acadesine 396. Acetylcholine Chloride 397. Acipimox 398. Aciclovir 399. Nifedipine 400. Amiloride HCl 401. Amlodipine besylate (Norvasc) 402. Chlorpheniramine Maleate 403. Fenoprofen Calcium 404. Erdosteine 405. Betaxolol hydrochloride (Betoptic) 406. Proparacaine HCl 407. Pranlukast 408. Oxfendazole 409. Carvedilol 410. Atracurium Besylate 411. Butoconazole nitrate 412. Azithromycin 413. Albendazole Oxide 414. Flubendazole 415. Chloroxine 416. Lomustine 417. Chenodeoxycholic Acid 418. Cimetidine 419. Clemastine Fumarate 420. Curcumin 421. Bifonazole 422. Pefloxacin Mesylate 423. Metoprolol Tartrate 424. Diethylstilbestrol 425. Diltiazem HCl 426. Diphenhydramine HCl 427. Dapoxetine
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT *IPERTEN/ARTEDIL/MANYPER 10mg tablets IPERTEN/ARTEDIL/MANYPER 20mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION IPERTEN/ARTEDIL/MANYPER 10 mg tablets Each tablet contains: Manidipine hydrochloride 10mg Excipient with known effect: 119,61 mg lactose monohydrate/tablet IPERTEN/ARTEDIL/MANYPER 20 mg tablets Each tablet contains: Manidipine hydrochloride 20mg Excipient with known effect: 131,80 mg lactose monohydrate/tablet For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet IPERTEN/ARTEDIL/MANYPER 10mg: pale yellow, round, scored tablet; IPERTEN/ARTEDIL/MANYPER 20mg: yellow-orange, oblong, scored tablet. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Mild to moderate essential hypertension 4.2 Posology and method of administration The recommended starting dose is 10 mg once a day. Should the antihypertensive effect be still insufficient after 2-4 weeks of treatment, it is advisable to increase the dosage to the usual maintenance dose of 20 mg once a day. Elderly In view of the slowing down of metabolism in the elderly, the recommended dose is 10mg once daily. This dosage is sufficient in most elderly patients; the risk/benefit of any dose increase should be considered with caution on an individual basis. Renal impairment In patients with mild to moderate renal dysfunction care should be taken when increasing the dosage from 10 to 20mg once a day. Hepatic impairment Due to the extensive hepatic metabolisation of manidipine, patients with mild hepatic dysfunction should not exceed 10mg once a day (see also Section 4.3 Contraindications). Tablet must be swallowed in the morning after breakfast, without chewing it, with a few liquid.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Galeterone for the Treatment of Castration- Resistant Prostate Cancer Bruce Montgomery1, Mario A
    Published OnlineFirst November 2, 2015; DOI: 10.1158/1078-0432.CCR-15-1432 Cancer Therapy: Clinical Clinical Cancer Research Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration- Resistant Prostate Cancer Bruce Montgomery1, Mario A. Eisenberger2, Matthew B. Rettig3, Franklin Chu4, Roberto Pili5, Joseph J. Stephenson6, Nicholas J. Vogelzang7, Alan J. Koletsky8, Luke T. Nordquist9, William J. Edenfield10, Khalid Mamlouk11, Karen J. Ferrante11, and Mary-Ellen Taplin12 Abstract Purpose: Galeterone is a selective, multitargeted agent that Results: In ARMOR1, across all doses, 49.0% (24/49) achieved a inhibits CYP17, antagonizes the androgen receptor (AR), and 30% decline in prostate-specific antigen (PSA; PSA30) and reduces AR expression in prostate cancer cells by causing an 22.4% (11/49) demonstrated a 50% PSA decline (PSA50). In increase in AR protein degradation. These open-label phase I ARMOR2 part 1, across all doses, PSA30 was 64.0% (16/25) and and II studies [Androgen Receptor Modulation Optimized PSA50 was 48.0% (12/25). In the 2,550-mg dose cohort, PSA30 for Response-1 (ARMOR1) and ARMOR2 part 1] evaluated was 72.7% (8/11) and PSA50 was 54.5% (6/11). Galeterone was the efficacy and safety of galeterone in patients with treat- well tolerated; the most common adverse events were fatigue, ment-naive nonmetastatic or metastatic castration-resistant increased liver enzymes, gastrointestinal events, and pruritus. Most prostate cancer (CRPC) and established a dose for further were mild or moderate in severity and required no action and there study. were no apparent mineralocorticoid excess (AME) events.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • The Repurposing Drugs in Oncology Database
    ReDO_DB: the repurposing drugs in oncology database Pan Pantziarka1,2, Ciska Verbaanderd1,3, Vidula Sukhatme4, Rica Capistrano I1, Sergio Crispino1, Bishal Gyawali1,5, Ilse Rooman1,6, An MT Van Nuffel1, Lydie Meheus1, Vikas P Sukhatme4,7 and Gauthier Bouche1 1The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium 2The George Pantziarka TP53 Trust, London, UK 3Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium 4GlobalCures Inc., Newton, MA 02459 USA 5Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 USA 6Oncology Research Centre, Vrije Universiteit Brussel, Brussels, Belgium 7Emory University School of Medicine, Atlanta, GA 30322 USA Correspondence to: Pan Pantziarka. Email: [email protected] Abstract Repurposing is a drug development strategy that seeks to use existing medications for new indications. In oncology, there is an increased level of activity looking at the use of non-cancer drugs as possible cancer treatments. The Repurposing Drugs in Oncology (ReDO) project has used a literature-based approach to identify licensed non-cancer drugs with published evidence of anticancer activity. Data from 268 drugs have been included in a database (ReDO_DB) developed by the ReDO project. Summary results are outlined and an assessment Research of clinical trial activity also described. The database has been made available as an online open-access resource (http://www.redo-project. org/db/). Keywords: drug repurposing, repositioning, ReDO project, cancer drugs, online database Published: 06/12/2018 Received: 27/09/2018 ecancer 2018, 12:886 https://doi.org/10.3332/ecancer.2018.886 Copyright: © the authors; licensee ecancermedicalscience.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma: a Single-Centre, Observer-Blinded, Randomized Controlled Trial (Trace)
    TRANEXAMIC ACID IN THE TREATMENT OF RESIDUAL CHRONIC SUBDURAL HEMATOMA: A SINGLE-CENTRE, OBSERVER-BLINDED, RANDOMIZED CONTROLLED TRIAL (TRACE) by Adriana Micheline Workewych A thesis submitted in conformity with the requirements for the degree of Master of Science Institute of Medical Science University of Toronto © Copyright by Adriana Micheline Workewych 2018 TRANEXAMIC ACID IN THE TREATMENT OF RESIDUAL CHRONIC SUBDURAL HEMATOMA: A SINGLE-CENTRE, OBSERVER-BLINDED, RANDOMIZED CONTROLLED TRIAL (TRACE) Adriana Micheline Workewych Master of Science Institute of Medical Science University of Toronto 2018 ABSTRACT Chronic subdural hematoma (CSDH) is a frequent consequence of head trauma, particularly in older individuals. Given the aging of populations globally, its incidence is projected to increase substantially. Hyperfibrinolysis may be central to CSDH enlargement by causing excessive clot degradation and liquefaction, impeding resorption. The only current standard treatment for CSDH is surgery, however, up to 31% of residual hematomas enlarge, requiring reoperation. Tranexamic acid (TXA), an antifibrinolytic medication that prevents excessively rapid clot breakdown, may help prevent CSDH enlargement, potentially eliminating the need for repeat surgery. To evaluate the feasibility of conducting a trial investigating TXA efficacy in residual CSDH, we conducted an observer-blinded, pilot randomized controlled trial (RCT). We showed this trial was feasible and safe, reporting only minor to moderate AEs, and an attrition rate of 4%. The results from this study will inform the conduct of a double-blinded RCT investigating TXA efficacy in post-operative CSDH management. ii ACKNOWLEDGEMENTS First, I would like to thank my supervisor Dr. Michael Cusimano, my mentor for nearly six years. You have always given me more opportunity than I could have ever hoped for – I could not ask for a more dedicated teacher.
    [Show full text]
  • Download Product Insert (PDF)
    Product Information Galeterone Item No. 17586 N CAS Registry No.: 851983-85-2 Formal Name: 17-(1H-benzimidazol-1-yl)-androsta- 5,16-dien-3β-ol N Synonym: TOK-001 MF: C26H32N2O FW: 388.6 H Purity: ≥98% H H Stability: ≥2 years at -20°C Supplied as: A crystalline solid HO Laboratory Procedures For long term storage, we suggest that galeterone be stored as supplied at -20°C. It should be stable for at least two years. Galeterone is supplied as a crystalline solid. A stock solution may be made by dissolving the galeterone in the solvent of choice. Galeterone is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of galeterone in ethanol and DMSO is approximately 20 mg/ml and approximately 30 mg/ml in DMF. Galeterone is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, galeterone should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Galeterone has a solubility of approximately 0.2 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. The cytochrome P450 (CYP) isoform CYP17 is also known as steroid 17α-hydroxylase/17,20 lyase because it catalyzes both 17α-hydroxylase and 17,20 lyase reactions in the synthesis of steroids, including androgens, estrogens, glucocorticoids, 1 and mineralocorticoids. Galeterone is a CYP17 inhibitor (IC50 = 300 nM) that has been shown to competitively block synthetic androgen binding (EC50 = 845 nM) and to antagonize the androgen receptor in transcriptional activation 2 assays.
    [Show full text]
  • No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis
    Hindawi BioMed Research International Volume 2020, Article ID 4097170, 11 pages https://doi.org/10.1155/2020/4097170 Research Article No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis Yang An,1,2 Zhaohui Bai,1,2 Xiangbo Xu,1,2 Xiaozhong Guo ,1 Fernando Gomes Romeiro ,3 Cyriac Abby Philips,4 Yingying Li,5 Yanyan Wu,1,6 and Xingshun Qi 1 1Department of Gastroenterology, General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area), Shenyang 110840, China 2Postgraduate College, Shenyang Pharmaceutical University, Shenyang 110016, China 3Department of Internal Medicine, Botucatu Medical School, UNESP-Univ Estadual Paulista. Av. Prof. Mário Rubens Guimarães Montenegro, s/n Distrito de Rubião Jr, Botucatu, Brazil 4The Liver Unit and Monarch Liver Lab, Cochin Gastroenterology Group, Ernakulam Medical Center, Kochi, 682028 Kerala, India 5Department of Gastroenterology, The First People’s Hospital of Huainan, Huainan 232007, China 6Postgraduate College, Jinzhou Medical University, Jinzhou 121001, China Correspondence should be addressed to Xingshun Qi; [email protected] Received 28 February 2020; Revised 25 May 2020; Accepted 1 June 2020; Published 27 June 2020 Academic Editor: Hongqun Liu Copyright © 2020 Yang An et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background and Aims. Acute upper gastrointestinal bleeding (AUGIB) is one of the most life-threatening emergency conditions. Hemostatic drugs are often prescribed to control AUGIB in clinical practice but have not been recommended by major guidelines and consensus.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]